



Nasal Type T/NK-cell Lymphoma: a rare case presenting as a palatal ulcer

Journal:	<i>Journal of Oral Science</i>
Manuscript ID	Draft
Manuscript Type:	Case Report
Date Submitted by the Author:	n/a
Complete List of Authors:	Celentano, Antonio; University Federico II of Naples, Department of Neuroscience, Reproductive and Odontostomatological sciences; University of Melbourne Faculty of the VCA and MCM, Melbourne Dental School & Oral Health CRC Mascolo, Massimo; University Federico II of Naples, Department of Advanced Biomedical Sciences, Pathology Section Adamo, Daniela; University Federico II of Naples, Department of Neuroscience, Reproductive and Odontostomatological sciences Ruoppo, Elvira; University Federico II of Naples, Department of Neuroscience, Reproductive and Odontostomatological sciences De Rosa, Gaetano; University Federico II of Naples, Department of Advanced Biomedical Sciences, Pathology Section Mignogna, Michele; University Federico II of Naples, Department of Neuroscience, Reproductive and Odontostomatological sciences
Keywords:	oral ulceration, Peripheral T-cell and NK-cell lymphomas, Nasal Type T/NK-cell Lymphoma, Lymphoma, T/NK cell NHL

SCHOLARONE™
Manuscripts

1 **Title: Nasal Type T/NK-cell Lymphoma: a rare case presenting as a palatal ulcer**

2

3 **Authors:** Antonio Celentano^{12*}, Massimo Mascolo³, Daniela Adamo¹, Elvira
4 Ruoppo¹, Gaetano De Rosa³, Michele Davide Mignogna¹

5

6 1: University Federico II of Naples, Department of Neuroscience, Reproductive and
7 Odontostomatological Sciences, Via Pansini n.5, Naples, 80131, Italy.

8 2: The University of Melbourne, Melbourne Dental School and Oral Health CRC, 720
9 Swanston street, Melbourne, 3053, Victoria, Australia.

10 3: University Federico II of Naples, Department of Advanced Biomedical Sciences,
11 Pathology Section, Via Pansini n.5, Naples, 80131, Italy.

12

13

14 ***CORRESPONDENCE:** Dr. Antonio Celentano, Department of Neuroscience,
15 Reproductive and Odontostomatological Sciences, University Federico II of Naples,
16 Via Pansini 5, Naples, 80131, Italy; Melbourne Dental School, Oral Health CRC, The
17 University of Melbourne, 720 Swanston street, 3053, Melbourne, Victoria, Australia.

18 antony.celentano@gmail.com, antonio.celentano@unina.it,

19 acelentano@unimelb.edu.au

20

21

22

23

24 **Abstract**

25 Nasal-Type T/NK-cell Lymphoma are very rare clinical entities, highly aggressive
 26 and with a dramatic prognosis. The case of a 37 year-old immunocompetent man with
 27 the main complaint of a deep palatal ulceration is presented. The patient had a three
 28 month medical history of his symptoms being underestimated and misdiagnosed by
 29 physicians. The diagnosis of extranodal T/NK-cell lymphoma nasal type was
 30 achieved in fifteen days but the patient clinical status worsened severely. Head and
 31 neck specialists must consider these clinical entities from the early symptoms.
 32 Because of their highly aggressive behavior, earlier therapies should be started before
 33 completing the diagnostic pathway.

34
 35 **Keywords:** Nasal Type T/NK-cell Lymphoma; T/NK cell NHL; Lymphoma;
 36 Peripheral T-cell and NK-cell lymphomas; oral ulceration

37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48

49 Introduction

50 Lymphoma, or lymphatic cancer, is a broad term encompassing a variety of cancers of
51 the lymphatic system. Lymphomas in humans are generally classified in two main
52 groups: the Hodgkin lymphomas (HL), also known as Hodgkin disease, and the non-
53 Hodgkin lymphomas (NHL). Non-Hodgkin lymphomas are divided into B- and T-cell
54 neoplasms and NK-cell lymphomas (1,2).

55 Natural killer (NK) cells are a third lymphocyte lineage, in addition to B- and T-cells,
56 that mediate cytotoxicity without prior sensitization. NK cells also have phenotypic
57 and genotypic characteristics; they express the NK-related antigen CD56 and T-cell
58 markers such as CD2 and CD3 epsilon, but their T-cell receptor (TCR) locus is not
59 rearranged (1).

60 Included in the NHL group are the Peripheral T-cell and NK-cell lymphomas
61 (PTNKCLs), a wide family of lymphomas with different clinicopathologic features,
62 which represent only 10%-20% of all NHLs in the Western world (2).

63 PTKNCLs are defined as angiocentric lymphomas in the revised European American
64 Lymphoma (R.E.A.L.) classification and include the "nasal" and the "nasal type"
65 varieties, which are very rare clinical entities in the United States and Europe, but
66 more common in Asia and Central America (3). Nasal T/natural killer (NK) cell
67 lymphoma is a distinct clinicopathologic entity highly associated with Epstein-Barr
68 virus (EBV) and with a very poor response to treatment and prognosis (5-year overall
69 survival rate of 25%) (3-6).

70 Generally a variety of cells ranging from small or medium-sized cells to large
71 transformed cells can characterize the broad cytologic spectrum of this entity. Tissue
72 damage is a common morphological feature of this form and is due to both the
73 cytotoxicity of the T/NK lymphoma cells as well as to angiocentricity (4,5,7).

74 The characteristic immunophenotype of Nasal T/NK cell lymphoma is distinguished
75 by a CD2 and CD56 positivity, but usually a negativity for surface CD3.

76 The presence of EBV in early diagnosis can be effectively evaluated by in situ
77 hybridization.

78 The differential diagnosis includes lymphomatoid granulomatosis, blastic or
79 monomorphic NK cell lymphoma/leukemia, CD56-positive peripheral T-cell
80 lymphoma, and enteropathy-associated T-cell lymphoma (4).

81 Extranodal sites like the skin, the subcutis and the gastrointestinal tract can be
82 affected by tumors with an identical phenotype and genotype. These extranodal forms
83 should be referred to as nasal-type T/NK cell lymphomas (4).

84 Here, we present a rare case of a 37-year-old Caucasian man affected by nasal-type
85 T/NK-cell lymphoma, referred to our institution with a 3 month delay between the
86 development of the first symptoms and our first medical examination.

87 The purpose of this study is to update data on the clinical and histopathological
88 findings of this rare disease, pointing out how misdiagnoses are responsible for
89 therapeutic delays and consequently of a worse prognosis for these aggressive forms.

90

91 **Case report**

92 A 37 year-old Caucasian man was referred to our Oral Medicine Unit, Department of
93 Head and Neck Diseases, Federico II University of Naples, with the main complaint
94 of a wide symptomatic ulcerative lesion of the hard palate.

95 His familial anamnesis encompasses 3 uncles who had died of different forms of
96 cancer in recent years (2 of lung cancer, and 1 of bowel cancer). The patient's medical
97 history was negative and he was in apparent good health except for a weak
98 hypercholesterolemia.

99 His first referred symptoms were a moderate submandibular lymphadenopathy and
100 weak fever starting 2 months before, for which reason he consulted the family doctor
101 who requested hematological tests with the main suspicion of an EBV/CMV
102 infection. The results of all the tests performed were negative and for one month the
103 patient received a symptomatic therapy. Four weeks later the patient started to
104 complain of a sense of nasal obstruction, with a breathing difficulty for which he
105 consulted an otorhinolaryngologist who performed an endoscopic examination of the
106 nasal cavities finding suppurative exudate and inflammation of the nasal floor and
107 lateral/medial walls. It was diagnosed as severe maxillary sinusitis and therapy with
108 corticosteroids through an aerosol and antibiotics was prescribed. After one month,
109 without any improvement of the symptoms, the patient started to complain of the first
110 oral symptom, a pain due to a swelling and ulcerated area in the median area of the
111 hard palate. For this reason he consulted his dentist who advised him to undergo an
112 oral medicine consultation at our hospital. Our first examination was performed soon
113 after and the patient was presented with the clinical condition shown in Figure 1.

114 The patient, after providing his written informed consent, was hospitalized and
115 examined by routine hematological tests which revealed a glucose level of 120 mg/dL
116 (normal range, 60 to 110), a total cholesterol level of 200 mg/dL (normal value up to
117 190), a Triglyceride level of 218 mg/dL (normal value up to 180) and an iron level of
118 49 µg/dL (normal range, 55 to 160).

119 The physical examination showed a widespread ulcerative and proliferative lesion
120 involving the hard palate, and marginally the soft palate and the left maxillary
121 alveolar process (Figure 1). The lesion measured about 4 cm at its maximum diameter
122 and showed a central zone of deep and extensive necrosis, with a surrounding area of
123 hyperplastic tissue weakly brown coloured. Two incisional biopsies of the lesion were

124 performed.

125 After 2 weeks, while the patient underwent a diagnostic pathway, the lesion presented
 126 with a considerably worse clinical evolution as shown in Figure 2.

127 At histology, scanning magnification revealed a dense and diffuse proliferation of
 128 pleomorphic small and medium sized lymphocytes within the entire chorion, with
 129 overlying extensive squamous epithelium ulceration. An angiocentric pattern of
 130 infiltration was evident. The predominant cell type was lymphocyte with round
 131 nuclei, one or more nucleoli and a scant cytoplasm. Numerous mitotic figures were
 132 seen and areas of necrosis were also present (figure 3A, 3B, 3C).

133 The neoplastic cells expressed CD2 and CD3; a weak expression of CD56 and
 134 granzyme B was observed (figure 3D). CD8 and CD30 were consistently negative.

135 The tumor had a proliferative fraction (Ki-67/MIB1) approaching approximately 70-
 136 75%. The analysis of the presence of EBV was performed with the FISH (fluorescent
 137 in situ hybridization) technique (Dako PNA ISH EBERER PNA Probe) and revealed
 138 a widespread positivity for EBV.

139 A diagnosis of extranodal NK/T-cell lymphoma, nasal type was made.

140 The patient was immediately referred to the Hematoncology Department to complete
 141 the staging and start treatment of the disease. A head/neck and chest computed
 142 tomography (CT) scan and a total body positron emission tomography (PET) scan
 143 were negative except for the oral and left nasal cavity involvement. Chemotherapy
 144 was therefore started.

145 At present the patient has developed a palatal perforation with an oronasal fistula
 146 (figure 4).

147 The study has been approved by the Ethics Committee of the University “Federico II”
 148 of Naples. Appropriate written informed consent has been obtained from the patient

149 included in the study.

150

151 **Discussion**

152 PTNKCLs are rare and heterogeneous forms of NHL that are usually characterized by
153 a very poor clinical outcome. Furthermore, many subtypes are currently present in the
154 World Health Organization (WHO) classification of PTCL (8).

155 As confirmed by our experience, the diagnosis of these forms is difficult for the
156 general practitioner as well as for medical specialists, a difficulty compounded by the
157 frequent underestimation/misdiagnosis of the first symptoms. Each failure in a
158 diagnostic step is usually followed by a delay of several weeks for the patient to
159 achieve the correct diagnosis and to undergo the specific therapy.

160 Because of the overall relative rarity of this condition, achieving the correct diagnosis
161 can be a challenge also for many pathologists. In a recent study conducted before the
162 most recent WHO classification the overall diagnostic accuracy among experts was
163 found to be approximately 81% with a value ranging from 67% to 95% depending on
164 the specific subtype (9).

165 In our case, prompt biopsies and relative histopathological examination led us to a fast
166 diagnosis in only two weeks, but unfortunately the patient had already undergone a 3
167 month delay since the first medical examination.

168 The head and neck health care specialists may be called as the main actors in the
169 diagnostic pathway of these rare diseases and, in presence of lack of response to first
170 treatments, the physicians are obliged to increase immediately the level of suspicion.

171 The first observation/waiting period must be not longer than two weeks, and should
172 be followed by a fast histopathological examination in all the uncertain cases.

173 Further examinations such as a maxillofacial CT scan and a head and neck ultrasound

174 test could be very usefull to have a presumed initial staging of the disease since the
175 first visits.

176 Based on this experience, it is arguably not correct to wait even three days in respect
177 of these forms of lymphomas in which the cytotoxicity and angiocentricity can
178 produce such a fast and deep necrosis. The grievous impairment of the surrounding
179 anatomical structures is the main complication that contributes to the already very
180 poor prognosis.

181 Furthermore in these highly aggressive forms the possibility of starting a therapy
182 before completing the diagnostic pathway should be evaluated. Starting an earlier
183 therapy could make a significant difference in improving such poor survival rates.

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199 **References**

- 200 1) Kato N, Yasukawa K, Onozuka T, Kikuta H (1999) Nasal and nasal-type T/NK-
201 cell lymphoma with cutaneous involvement. *J Am Acad Dermatol.* 40, 850-6.
- 202 2) Cotta CV, Hsi ED (2008) Pathobiology of mature T-cell lymphomas. *Clin*
203 *Lymphoma Myeloma.* 8, 168–179.
- 204 3) Rodriguez J, Romaguera JE, Manning J, Ordonez N, Ha C, Ravandi F, Cabanillas
205 F (2000) Nasal-type T/NK lymphomas: a clinicopathologic study of 13 cases. *Leuk*
206 *Lymphoma.* 39, 139-44.
- 207 4) Jaffe ES, Chan JK, Su IJ, Frizzera G, Mori S, Feller AC, Ho FC (1996) Report of
208 the Workshop on Nasal and Related Extranodal Angiocentric T/Natural Killer Cell
209 Lymphomas. Definitions, differential diagnosis, and epidemiology. *Am J Surg Pathol.*
210 20, 103-11.
- 211 5) Yoon TY, Lee HT, Chang SH (1999) Nasal-type T/natural killer cell angiocentric
212 lymphoma, Epstein-Barr virus-associated, and showing clonal T-cell receptor gamma
213 gene rearrangement. *Br J Dermatol.* 140, 505-8.
- 214 6) Takata K, Hong ME, Sitthinamsuwan P, Loong F, Tan SY, Liau JY, Hsieh PP, Ng
215 SB, Yang SF, Pongpruttipan T, Sukpanichnant S, Kwong YL, Hye Ko Y, Cho YT,
216 Chng WJ, Matsushita T, Yoshino T, Chuang SS (2015) Primary Cutaneous NK/T-cell
217 Lymphoma, Nasal Type and CD56-positive Peripheral T-cell Lymphoma: A Cellular
218 Lineage and Clinicopathologic Study of 60 Patients From Asia. *Am J Surg Pathol.* 39,
219 1-12.
- 220 7) Ohshima K, Suzumiya J, Shimazaki K, Kato A, Tanaka T, Kanda M, Kikuchi M
221 (1997) NasalT/NK cell lymphomas commonly express perforin and Fas ligand:
222 important mediators of tissue damage. *Histopathology.* 31, 444-50.

223 8) Ohshima K (2014). Pathological diagnosis of mature T/NK cell lymphoma. Nihon
224 Rinsho. 72, 445-9.

225 9) Hsi ED, Said J, Macon WR, Rodig SJ, Ondrejka SL, Gascoyne RD, Morgan EA,
226 Dorfman DM, Maurer MJ, Dogan A (2014) Diagnostic accuracy of a defined
227 immunophenotypic and molecular genetic approach for peripheral T/NK-cell
228 lymphomas. A North American PTCL study group project. Am J SurgPathol. 38, 768-
229 75.

230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247

248 **Figure legends:**

249 **Figure 1:** Intraoral clinical aspect in patient with T/NK-cell angiocentric lymphoma at
250 first examination. The hard palate and the alveolar process presented with an
251 ulcerative and destructive lesion at the first examination with an extensive zone of
252 necrosis.

253 **Figure 2:** The clinical aspect of the patient after 2 weeks.

254 **Figure 3:** Extranodal NK/T-cell lymphoma, nasal type. a) low magnification showing
255 a dense and diffuse infiltrate of pleomorphic lymphocytes within the entire chorion
256 with an angiocentric pattern of infiltration (hematoxylin and eosin, x25); b) prominent
257 tumor necrosis was seen (hematoxylin and eosin, x100); c) medium-sized
258 pleomorphic lymphocytes predominate (hematoxylin and eosin, x200); and d) most
259 cells strongly express CD2 (CD2, x25).

260 **Figure 4:** The intraoral examination after 5 weeks shows a palatal perforation with an
261 oronasal fistula.

262




Figure 1
254x169mm (300 x 300 DPI)

Review



Figure 2
254x169mm (300 x 300 DPI)

Review




Figure 3
833x631mm (72 x 72 DPI)

review



Figure 4
451x338mm (72 x 72 DPI)

review